An ELISA for the measurement of VP16 (etoposide) in unextracted plasma.
An ELISA for the anti-cancer drug VP16 in unextracted plasma has been developed using VP16-thyroglobulin-coated microtitre plates, a sheep anti-VP16 serum, and a donkey anti-sheep HRPO-labelled second antibody. The sensitivity of the assay was 0.5 ng/ml, providing a detection limit of 0.1 microgram VP16/ml plasma. Plasma interference effects were negligible and therefore the standard curve could be set up in assay buffer. A good correlation was obtained between the ELISA and established HPLC and RIA methods. No evidence was found of significant levels of cross-reacting metabolites in plasma samples obtained from patients receiving VP16 therapy. The antiserum did not cross-react with the epiaglycone of VP16.
Henneberry
H P
HP
Department of Biochemistry, University of Surrey, Guildford, U.K.
Aherne
G W
GW
Marks
V
V
D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005047:Etoposide / Q000031:analogs & derivatives / Q000097:blood*; D006801:Humans; D007202:Indicators and Reagents
D007202:Indicators and Reagents; D005047:Etoposide